What Is Cardiogen?
Cardiogen is the name used for an experimental four-amino-acid peptide from the Russian short-peptide bioregulator programme. Reviews from its originating research group identify it as Ala-Glu-Asp-Arg, abbreviated AEDR.
The name suggests a relationship with the heart, but names are not evidence of tissue targeting. Published work includes rat heart-tissue cultures, mouse embryonic fibroblasts and an unrelated rat tumour model. No published study was identified in which people received Cardiogen for heart attack, heart failure or any other condition.
Cardiogen is not an approved medicine. Claims that it repairs heart muscle or prevents cardiovascular disease go beyond the available evidence.
What is Cardiogen made from?
The sequence reported in the originating group's reviews is:
`Ala-Glu-Asp-Arg (AEDR)`
These letters represent alanine, glutamic acid, aspartic acid and arginine. A tetrapeptide contains four amino-acid residues linked by three peptide bonds.
The strongest indexed sequence-specific paper calls the compound H-Ala-Glu-Asp-Arg-OH rather than Cardiogen. Other papers use the trade-style name without stating a sequence in their abstracts. The name-to-sequence connection therefore rests mainly on the developers' later tables and reviews, not on an independent identity study.
Cardiogen must not be confused with CardioGen-82, a rubidium-82 generator used for positron-emission tomography heart imaging. That regulated diagnostic product is unrelated to this peptide.
What does “heart bioregulator” mean?
Researchers associated with Vladimir Khavinson proposed that very short peptides could influence gene activity in particular tissues. Cardiogen was assigned to cardiac research within that framework.
This does not show that AEDR travels selectively to heart muscle after entering an animal or person. Tissue targeting requires distribution measurements, target engagement and evidence that other organs are spared. No published human study provides those data.
What did the rat heart-tissue study examine?
Researchers used organotypic cultures from the myocardium of three-month-old and 24-month-old rats. Myocardium means heart muscle. An organotypic culture keeps small pieces of tissue outside the body so that some cell-to-cell relationships remain intact.
The experiment compared 20 individual amino acids and Cardiogen at a very low laboratory concentration. Seven amino acids stimulated cell proliferation in cultures from young rats. Cardiogen affected proliferation and apoptosis, the orderly process of programmed cell death, particularly in tissue from older animals.
This design can explore cell behaviour, but it does not measure a beating heart, blood flow, exercise capacity or survival. The tissue had been removed from the animal, so the study could not test absorption, metabolism, delivery to the heart or whole-body toxicity.
What did the structural-protein study find?
A 2012 paper exposed cultured mouse embryonic fibroblasts to the AEDR tetrapeptide. Fibroblasts make structural material around cells and are not heart-muscle cells.
The authors reported twofold to fivefold increases in actin, tubulin and vimentin, which help form the cellular skeleton. Lamin A and lamin C, proteins supporting the nucleus, increased by twofold to threefold. The authors proposed that these changes could support cell proliferation and reduce apoptosis.
Protein-expression changes are laboratory measurements. More of a structural protein is not proof of healthier heart muscle, regeneration after an infarction or protection against heart failure. The cells came from mouse embryos, which also limits relevance to an ageing human heart.
Was Cardiogen tested after a heart attack?
Some later reviews from the same research network describe AEDR in a rat myocardial-infarction model and report lower mortality. A myocardial infarction is a heart attack caused by loss of blood supply to heart muscle.
The accessible reviews do not provide enough primary-study information to assess allocation, masking, animal numbers, exclusions, treatment composition or independent replication. A review statement cannot replace a complete primary report. The claim should therefore be treated as unresolved rather than as established evidence that Cardiogen improves survival.
Why was it studied in a tumour model?
Researchers injected Cardiogen in old rats bearing M-1 sarcoma, an experimental connective-tissue tumour. They reported dose-related inhibition of tumour growth, bleeding-related tissue death and increased tumour-cell apoptosis.
This was not a cardiovascular experiment. The authors suggested an effect involving the tumour's blood vessels, but that does not establish repair or protection of ordinary blood vessels. Results from a rat sarcoma cannot be used to claim human anti-cancer or heart benefits.
Has Cardiogen been tested in humans?
No published human treatment study or registered clinical trial was identified through October 2026. There is no reported Phase I programme defining initial safety and pharmacokinetics, meaning how the body absorbs, distributes, breaks down and clears the peptide.
There is also no controlled evidence for blood pressure, heart rhythm, cardiac biomarkers, echocardiography, hospital admission, exercise tolerance or survival.
What would evidence of heart repair need to show?
Heart repair is a demanding claim because adult heart-muscle cells have limited capacity to replace themselves after major injury. A useful experiment would first need to show that intact Cardiogen reaches heart tissue at a measured concentration. Researchers would then need to demonstrate an effect on cardiac cells rather than on general cell-growth markers alone.
Animal studies would normally examine the amount of damaged tissue, formation of scar tissue, electrical stability and pumping performance. Echocardiography, an ultrasound examination of the heart, can measure the percentage of blood expelled by the main pumping chamber with each beat. Pressure and volume measurements can add information about how the heart fills and contracts.
Human trials would need outcomes that matter to patients. Depending on the proposed use, these might include symptoms, walking capacity, hospital admission, recurrent heart attack and cardiovascular death. A rise in actin or a fall in p53 in cultured tissue would not substitute for these outcomes.
None of this evidence chain has been completed for Cardiogen. The available studies sit near its beginning.
Could increased cell proliferation be harmful?
Cell proliferation means an increase in cell number. It can support tissue maintenance, but it is not automatically beneficial. Mature heart-muscle cells rarely divide, while fibroblasts and other supporting cells can multiply after injury. Excess fibroblast activity contributes to fibrosis, the formation of stiff scar tissue that can impair filling and electrical conduction.
The rat tissue-culture paper does not show which cell populations accounted for the measured growth zone around an explant. It therefore cannot establish that new functional cardiomyocytes were produced. The tumour experiment also reminds us that growth, apoptosis and blood-vessel effects depend heavily on biological context.
A development programme would need to distinguish useful repair from fibrosis, abnormal vessel growth and unwanted proliferation elsewhere. Long-term observation would matter because short cell experiments may miss delayed changes.
Does Cardiogen act through gene regulation?
The broader short-peptide programme proposes that peptides interact with DNA, chromatin or regulatory proteins. Chromatin is the combination of DNA and packaging proteins inside the nucleus. Its organisation helps determine which genes are available for transcription, the process of making an RNA copy from DNA.
The AEDR fibroblast study measured increased structural proteins and interpreted them as part of a proposed protective response. It did not directly show AEDR binding a particular cardiac gene, promoter or transcription factor. It also did not establish selective entry into cardiomyocyte nuclei.
This leaves several steps unresolved: whether intact AEDR crosses a cell membrane, whether it enters the nucleus, what it binds, whether the interaction is sequence-specific and whether the resulting gene changes improve cardiac function. A proposed mechanism should not be presented as an established route of action until those links are measured directly.
How does Cardiogen compare with established cardiac medicines?
Approved cardiovascular medicines usually have a defined molecular target, manufacturing standard, dose form and clinical evidence for a particular population. Some reduce blood pressure or clotting. Others alter heart rate, fluid balance or hormonal signals that become harmful in heart failure.
Cardiogen has none of that clinical infrastructure. It has no authorised indication, standard formulation, validated human exposure or trial-based interaction profile. Calling it “cardioprotective” can obscure the fact that protection has not been demonstrated through human cardiac outcomes.
This does not prove that the peptide has no biological activity. It means its evidence cannot be placed alongside approved treatments as though both had passed comparable tests.
Can evidence from ageing rats answer questions about human ageing?
Older rats can model selected age-related cellular changes, but the species has a shorter lifespan, different cardiovascular physiology and different patterns of disease. The 24-month-old tissue cultures can indicate that age influenced the response of removed tissue. They cannot show that Cardiogen reverses cardiovascular ageing throughout a living organism.
Age-related heart disease in people is shaped by blood pressure, atherosclerosis, diabetes, kidney function, genetics, medicines and decades of exposure. A small peptide would need to be studied against that complexity. No evidence shows that Cardiogen reduces biological age or extends healthy human life.
What questions remain unanswered?
- Is the marketed Cardiogen name consistently attached to analytically confirmed AEDR?
- Does intact AEDR survive long enough in blood to reach the heart?
- Which cardiac and non-cardiac cell types take it up?
- Does it change contractile function rather than only protein expression?
- Could proliferation increase fibrosis or support abnormal cells?
- What organs clear it, and do repeated exposures change immunity?
- Can any effect be reproduced by an independent research group?
These gaps explain why the evidence remains preclinical even though the programme has existed for years.
How was Cardiogen developed?
| Period | Development |
|---|---|
| 1970s onward | Soviet and Russian groups developed tissue-derived peptide preparations and later proposed short synthetic sequences |
| 2000s | Cardiogen appeared in organ-associated short-peptide research and patents |
| 2009 to 2010 | Papers reported findings in rat heart-tissue cultures and an M-1 sarcoma model |
| 2012 | A sequence-specific AEDR paper examined structural proteins in mouse fibroblasts |
| 2020s | Reviews repeated proposed cardiac and gene-regulatory mechanisms without a clinical programme |
| Current position | Preclinical compound with no published human treatment study |
How is Cardiogen synthesised and checked?
AEDR can be assembled by solid-phase peptide synthesis. Protected amino acids are attached in the specified order while the growing chain remains fixed to a resin. Protecting groups prevent unwanted side reactions. The finished chain is released, deprotected and purified.
Identity testing can include mass spectrometry and sequence-sensitive fragmentation. Chromatography separates the intended peptide from shortened chains and other impurities. Tests may also measure peptide content, counterions, water and aggregation.
Material for a regulated sterile study would need additional controls for batch consistency, potency, bacterial endotoxins, particles, sterility and stability. A purity percentage alone does not establish pharmaceutical quality. This explanation is educational and does not provide a manufacturing recipe.
What is known about safety?
There is no adequate human safety record. Very short peptides may be broken down quickly, but Cardiogen's intact half-life, tissue exposure and clearance have not been established in people.
Potential research questions include effects on abnormal cell proliferation, immune reactions, blood pressure, rhythm, clotting and non-cardiac tissues. These are uncertainties, not documented adverse reactions. People with suspected heart disease require established assessment because delaying care can be dangerous.
Product identity adds another safety problem. A label may use the Cardiogen name without demonstrating sequence, peptide content, sterility or freedom from bacterial endotoxins. Endotoxins are inflammatory components of certain bacteria and can remain even when living bacteria are absent. Chemical purity does not answer microbiological or formulation questions.
Cardiovascular illness also creates little margin for uncertainty. Changes in fluid balance, blood pressure, rhythm or clotting can have serious consequences. The absence of reported adverse events in sparse papers must not be mistaken for evidence that these effects do not occur.
Is Cardiogen approved?
No. Cardiogen is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Does Cardiogen affect rat heart tissue outside the body? | Organotypic cultures | Cellular effects were reported |
| Does AEDR alter structural proteins? | Mouse embryonic fibroblasts | Selected proteins increased |
| Does it repair a living heart? | Incomplete preclinical reporting | Not established |
| Does it treat human heart disease? | No human treatment study | Unknown |
| Is it safe in people? | No adequate exposure study | Unknown |
| Is it approved? | No FDA, MHRA or EMA approval | No |
Frequently asked questions
What is Cardiogen?
It is an experimental short peptide associated with the Russian peptide-bioregulator programme.
What is its sequence?
It is usually reported as Ala-Glu-Asp-Arg, abbreviated AEDR.
Is Cardiogen a heart hormone?
No. It is not an established naturally circulating human cardiac hormone.
Does Cardiogen repair heart muscle?
No human evidence shows repair of damaged heart muscle.
Has it been tested after heart attack?
Later reviews describe a rat experiment, but accessible primary reporting is insufficient for a firm conclusion.
Does it improve heart failure?
No controlled human trial has tested symptoms, pumping function, admission or survival.
Is Cardiogen the same as CardioGen-82?
No. CardioGen-82 is an unrelated diagnostic imaging system.
Has Cardiogen been tested in people?
No published human treatment study was identified.
Is Cardiogen known to be safe?
No adequate human safety profile exists.
Is Cardiogen approved?
It is not approved by the FDA, MHRA or EMA.
Sources
Research reviewed through October 2026.